Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

3 Growth Stocks That Could Rocket Higher in 2023 ↗

January 06, 2023

Upcoming binary events could push these stocks to new all-time highs.

Via The Motley Fool

Alnylam Announces Updates to its Board of Directors

January 05, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes

December 21, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease ↗

October 07, 2022

Via Benzinga

Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 16, 2022

Via Benzinga

Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day

December 15, 2022

From Alnylam Pharmaceuticals

Via Business Wire

Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

December 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analyst Ratings for Alnylam Pharmaceuticals ↗

October 03, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Via Benzinga

Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval ↗

October 03, 2022

Via Benzinga

Alnylam to Webcast Virtual R&D Day

December 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗

December 06, 2022

Via Benzinga

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022

December 01, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 09, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗

November 02, 2022

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter.

Via Benzinga

What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

November 02, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year

October 27, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program ↗

October 27, 2022

Via Benzinga

Alnylam Pharmaceuticals: Q3 Earnings Insights ↗

October 27, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

October 27, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗

October 20, 2022

Despite enthusiasm in some camps, the risk of potential cures clouds market projections.

Via Investor's Business Daily

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 13, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company ↗

October 13, 2022

Via Benzinga

Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results

October 13, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 Top Biotech Stocks Defying the Bear Market ↗

October 11, 2022

Bear market, shmear market. These biotech stocks are soaring despite the market downturn.

Via The Motley Fool

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

October 06, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Where Alnylam Pharmaceuticals Stands With Analysts ↗

October 03, 2022

Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

October 03, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Via Benzinga

AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know ↗

October 02, 2022

Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...

Via Benzinga

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

September 30, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.